South Dakota Investment Council Sells 12,800 Shares of Solventum Corporation $SOLV

South Dakota Investment Council cut its holdings in shares of Solventum Corporation (NYSE:SOLV) by 5.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 242,825 shares of the company’s stock after selling 12,800 shares during the period. South Dakota Investment Council’s holdings in Solventum were worth $17,726,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. CHICAGO TRUST Co NA boosted its holdings in shares of Solventum by 3.0% during the 3rd quarter. CHICAGO TRUST Co NA now owns 5,188 shares of the company’s stock valued at $379,000 after acquiring an additional 150 shares during the last quarter. Deseret Mutual Benefit Administrators lifted its position in Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after purchasing an additional 163 shares during the period. Lazard Asset Management LLC lifted its position in Solventum by 1.4% during the second quarter. Lazard Asset Management LLC now owns 11,605 shares of the company’s stock valued at $880,000 after purchasing an additional 163 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Solventum by 2.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,963 shares of the company’s stock worth $436,000 after purchasing an additional 166 shares during the last quarter. Finally, Pacer Advisors Inc. grew its position in Solventum by 1.3% in the 3rd quarter. Pacer Advisors Inc. now owns 13,381 shares of the company’s stock worth $977,000 after purchasing an additional 168 shares during the period.

Analyst Upgrades and Downgrades

SOLV has been the topic of several research analyst reports. UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Wall Street Zen raised Solventum from a “hold” rating to a “buy” rating in a report on Saturday. Stifel Nicolaus boosted their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Finally, BTIG Research reiterated a “buy” rating and issued a $100.00 price objective on shares of Solventum in a research note on Friday. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.70.

Solventum Trading Down 1.6%

Shares of NYSE:SOLV opened at $73.05 on Tuesday. The stock has a 50 day moving average of $78.43 and a 200 day moving average of $76.24. The company has a market cap of $12.67 billion, a PE ratio of 8.24, a price-to-earnings-growth ratio of 6.75 and a beta of 0.40. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $88.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The company had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. Solventum’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, equities research analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its board has authorized a stock buyback program on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.